Health · Medical Research · 1 hr ago

First participant completes 36-week phase of Neurizon ALS trial

First participant completes 36-week phase of Neurizon ALS trial

Neurizon Therapeutics’ first trial participant completed the 36-week randomised phase of its study of NUZ-001, an experimental treatment for ALS.

The trial is part of a Phase 2/3 study run across 78 US clinical sites, with 250 participants enrolled.

ALS is the most common form of motor neurone disease, which affects nerve cells that control movement.

The participant moved into an optional extension where everyone receives NUZ-001, regardless of their original treatment assignment.

The extension will add longer-term safety and health data, but it is not a separate controlled test of whether the treatment works.

The main trial results are expected in late Q2 2027 and could support a regulatory submission if they meet applicable requirements.

Neurizon also drew down about $3.7 million from a financing facility, secured against its estimated FY27 R&D tax rebate, to help fund its trial commitments.

1 source

Related

What people are saying

Dr Chris BremerNeurizon Therapeutics CEO
The extension provides an opportunity to build our understanding of NUZ-001 through longer-term treatment
via Stockhead